European Commission authorises remdesivir for Covid-19 treatment

The EU has expedited the authorisation, approving the drug in an exceptionally short timeframe

The European Commission on Friday authorised anti-viral drug remdesivir for treatment against coronavirus, making it the first drug authorised at the European Union-level for the treatment of Covid-19.

"Today, the European Commission granted a conditional marketing authorisation for the medicine remdesivir," the European Commission said in a press release, Xinhua reported.

Stella Kyriakides, Commissioner for Health and Food Safety, said: "Today's authorisation of a first medicine to treat Covid-19 is an important step forward in the fight against this virus... We will leave no stone unturned in our efforts to secure efficient treatments or vaccine against the coronavirus."

The EU expedited the authorisation, approving the drug in an exceptionally short timeframe, but not before the news that the US has already locked down a large supply of remdesivir, made by Gilead Sciences, in the coming months.

The US Department of Health and Human Services confirmed Monday that it had secured all of the Gilead's production for July and 90 per cent of that for August and September for US hospitals, raising concerns in Europe.

A spokesman for the European Commission told a press conference on Thursday that Brussels heard of the US move from media reports, meaning Washington didn't bother to inform its allies beforehand. The EU was in ongoing talks with Gilead Sciences to reserve a "sufficient number of doses", reporters were told.